Compliance with estrogen replacement therapy: Current issues

Climacteric

Volumn 5, Issue SUPPL. 2, 2002, Pages 12-19

  Pitkin, J ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

Author keywords

Compliance; Continuation; Hormone replacement therapy; Uptake; Women's attitudes

Indexed keywords

ESTROGEN;

ARTICLE; DOCTOR PATIENT RELATION; ESTROGEN THERAPY; FEMALE; HUMAN; INDIVIDUALIZATION; INTERPERSONAL COMMUNICATION; LONG TERM CARE; MEDICAL EDUCATION; MEDICAL LITERATURE; MENOPAUSE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; PATIENT COMPLIANCE; PHYSICIAN-PATIENT RELATIONS; PULSE THERAPY, DRUG; TREATMENT REFUSAL;

EID: 0036389979     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Smith DC, Prentice R, Thompson DJ, Herrman WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164-7
2. Gambrell RD Jr. The prevention of endometrial cancer in postmenopausal women with progestogens. Maturitas 1978;1:107-12
3. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclical progestogen therapy in postmenopausal women. Lancet 1997;349:458-61
4. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and HRT: collaborative re-analysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-59
5. Hulley S, Grady D, Bush T, et al. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998;280:605-13
6. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92:722-7
7. Grodstein F, Martinez ME, Platz EA, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 1998;128:705-12
8. Smith W, Mitchell P, Wang JJ. Gender, oestrogen, hormone replacement and age-related macular degeneration: results from the Blue Mountains Eye Study. Aust NZ J Ophthalmol 1997;25(Suppl I)S13-5
9. Tang M-X, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age of onset of Alzheimer's disease. Lancet 1996;348:429-32
10. Royal College of Physicians. Osteoporosis. Clinical Guidelines for the Prevention and Treatment. London: RCP, 1999
11. Griffith S. A review of the factors associated with patient compliance and the taking of prescribed medicines. Br J Gen Pract 1990;40:114-16
12. Ravinkar VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987;156:1332-4
13. Stumpf PG, Trolice MP. Compliance problems with hormone replacement therapy. Obstet Gynecol Clin North Am 1994;21:219-28
14. McGavock H, Britten N, Weinman J. A review of the literature on drug adherence. Taking medicines to best effect. London: The Royal Pharmaceutical Society of Great Britain, 1995
15. Lopes P, Mensier A. Evaluation de l'équilibre risque-bénéfice du traitement hormonal substitutif de la ménopause et éléments susceptibles de maximiser l'observance. Contracept Fertil Sex 1998;26:412-16
16. Royal Pharmaceutical Society of Great Britain (RPSGB) Working Party. From Compliance to Concordance. Chairman: Professor Marshall Marinker. London: RPSGB, 1997
17. Cipolle R, Strand L, Morley P. Pharmaceutical Care Practice. New York: McGraw-Hill, 1998
18. The European Society of Human Reproduction and Embryology Capri Workshop Group. Continuation rates for oral contraceptives and hormone replacement therapy. Hum Reprod 2000;15:1865-71
19. Coope J, Marsh J. Can we improve compliance with long-term HRT? Maturitas 1992;15:151-8
20. Bryce FC, Lilford RJ. General practitioners' use of hormone replacement therapy in Yorkshire. Eur J Obstet Gynecol Reprod Biol 1990;37:55-61
21. Wilkes HC, Meade TW. Hormone replacement therapy in general practice: a survey of doctors in the MRC's general practice research framework. Br Med J 1991;302:1317-20
22. Oddens BJ, Boulet MJ, Lehert P, Visser AP. Has the climacteric been medicalized? A study on the use of medication for climacteric complaints in four countries. Maturitas 1992;15:171-81
23. Kenemans P, Barentsen R, van de Weijer R. Practical HRT, 2nd edn. Zeist, The Netherlands: Medical Forum International, 1996
24. Limouzin-Limothe MA. What women want from hormone replacement therapy: results of an international survey. Eur J Obstet Gynecol Reprod Biol 1996;64:S21-4
25. Lindgren R, Berg G, Hammar M, Zuccon E. Hormonal replacement therapy and sexuality in a population of Swedish postmenopausal women. Acta Obstet Gynecol Scand 1993;72:292-7
26. Li C, Samsioe G, Lidfelt J, Nerbrand C, Agardh CD. Important factors for use of hormone replacement therapy: a population-based study of Swedish women. The Women's Health in Lund Area (WHILA) Study. Menopause 2000;7:273-81
27. Koster A. Hormone replacement therapy: use patterns in 51-year-old Danish women. Maturitas 1990;12:345-56
28. Oddens BJ, Boulet MJ. Hormone replacement therapy among Danish women aged 45-65 years: prevalence, determinants and compliance. Obstet Gynecol 1997;90:269-77
29. Barrett-Connor E, Wingard DL, Criqui MH. Postmenopausal oestrogen use and heart disease risk factors in the 1980s. J Am Med Assoc 1989;261:2167-9
30. Hemminki E, Brambillia DJ, McKinley SM, Posner JG. Use of oestrogens among middle-aged Massachusetts women. Ann Pharmacother 1991;25:418-23
31. Jolleys JV, Olesen F. A comparative study of prescribing of hormone replacement therapy in USA and Europe. Maturitas 1996;23:47-53
32. Pilon D, Castilloux AM, Le Lorier J. Estrogen replacement therapy: determinants of persistence with treatment. Obstet Gynecol 2001;97:97-100
33. Hill DA, Weiss NS, La Croix AZ. Adherence to postmenopausal hormone therapy during the year after the initial prescription: a population-based study. Am J Obstet Gynecol 2000;182:270-6
34. Kotzan JA, Martin BC, Wade WE. Persistence with estrogen therapy in a postmenopausal Medicaid population. Pharmacotherapy 1999;19:363-9
35. Faulkner DL, Young C, Hutchins D, McCollam JS. Patient non compliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database. Menopause 1998;5:226-9
36. Castelo-Branco C, Figueras F, Sanjuan A, et al. Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: benefits to bone and analysis of factors associated with discontinuation. Menopause 1999;6:307-11
37. Chung TH, Lau TK, Cheung LP, Haines CJ. Compliance with hormone replacement therapy in Chinese women in Hong Kong. Maturitas 1998;28:213-19
38. Goldman GA, Kaplan B, Leiserowitz DM, Pardo Y, Amster R, Fisch B. Compliance with hormone replacement therapy. A comparative study. Clin Exp Obstet Gynecol 1998;25:18-19
39. Bjorn I, Backstrom T. Drug related negative side effects is a common reason for poor compliance in hormone replacement therapy. Maturitas 1999;32:77-86
40. National Opinion Poll. The Menopause Revolution: How Far Have We Come? UK Market research, 1992
41. Hope S, Rees MCP. Why do British women start and stop hormone replacement therapy? J Br Menopause Soc 1995;1:26-7
42. Lawrence M, Jones L, Lancaster T, Daly E, Banks E. Hormone replacement therapy: patterns of use studied through British general practice computerized records. Fam Pract 1999;16:335-42
43. Mattsson LA, Stadberg E, Milsom I. Management of hormone replacement therapy: the Swedish experience. Eur J Obstet Gynecol Reprod Biol 1996;64(Suppl):S3-5
44. Hunter M, O'Dea L, Britten N. Decision making and hormone replacement therapy: a qualitative analysis. Soc Sci Med 1997;45:1541-8
45. Guillemin MN. Managing menopause: a critical feminist engagement. Scand J Public Health 1999;27:273-8
46. Marmoreo J, Brown JB, Batty HR, Cummings S, Powell M. Hormone replacement therapy: determinants of women's decisions. Patient Educ Couns 1998;33:289-98
47. Bond M, Bywaters P. Towards understanding women's decisions to cease HRT. J Adv Nurs 1999;29:852-8
48. Pereiro Berenguer I, Sanfelix Genoves J, Garcia Cervera J, Furio Bonet S, Vicente Polo JM, Martinez Mir I. Compliance of hormone replacement therapy in menopausal women. Med Clin 2001;117:207-10
49. den Tonkelaar I, Oddens BJ. Determinants of long-term hormone replacement therapy and reasons for early discontinuation. Obstet Gynecol 2000;95:507-12
50. Keating NL, Cleary PD, Rossi AS. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999;130:545-53
51. Isaacs AJ, Britton AR, McPherson K. Utilisation of hormone replacement therapy by women doctors. Br Med J 1995;311:1399-1401
52. McNagy SE, Wenger NK, Frank E. Personal use of postmenopausal hormone replacement therapy by women physicians in the United States. Ann Intern Med 1997;127:1093-6
53. Andersson K, Pendersen AT, Mattsson LA, Milsom I. Swedish gynaecologists' and general practitioners' views on the climacteric period: knowledge, attitudes and management strategies. Acta Obstet Gynecol Scand 1998;77:909-16
54. Ettinger B, Pressman A, Silver P. Effect of age on reason for initiation and discontinuation of hormone replacement therapy. Menopause 1999;6:282-9
55. Khastgir G, Studd J. Patient's outlook, experience and satisfaction with hysterectomy, bilateral oophorectomy and subsequent continuation of hormone replacement therapy. Am J Obstet Gynecol 2000;183:1427-33
56. North American Menopause Society. Achieving long-term continuance of menopause ERT/HRT: consensus opinion of the North American Menopause Society. Menopause 1998;5:69-76
57. Rolnick S J, Kopher RA, Compo RB, Kelley ME, Defor TA. Provider attitudes and self-reported behaviour related to hormone replacement therapy. Menopause 1999;6:257-63
58. Allen S, Pitkin J. Establishing a menopause outreach nurse service: enhancing the primary/secondary care interface. J Br Menopause Soc 2000;6(Suppl 3):24
59. Tanna N, Pitkin J, Anderson C, Greene R. An assessment of the specialist menopause pharmacist role. The 9th International Menopause Society World Congress on Menopause, Yokohama, Japan. Monduzzi Editore, 1999:349-53
60. Wren BG, Brown L. Compliance with hormone replacement therapy. Maturitas 1991;13:17-21
61. Sturdee DW. The importance of patient education in improving compliance. Climacteric 2000:3(Suppl 2):9-13
62. Keating FS, Manassiev N, Stevenson JC. Maximising the use of HRT: focus on hysterectomised women. Curr Med Res Opin 1999;15:290-7